Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Health Canada Issues Notice Of Compliance For Gilead’s Single Tabletregimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine And Tenofoviralafenamide) For Treatment Of HIV-1 Infection
12/7/2015
-
European Medicines Agency Validates Gilead’s Marketing Application For Fixed-Dose Combination Of Sofosbuvir/Velpatasvir For The Treatment Of Hepatitis C
12/4/2015
-
New Report Accuses Gilead of Putting Profit Ahead of Patients
12/3/2015
-
Where Gilead May Be a Decade from Now
12/2/2015
-
Will Merck & Co. Be the One to Finally Take Down Gilead?
11/25/2015
-
Gilead To Present At Two Upcoming Investor Conferences On Tuesday, December 1
11/25/2015
-
European Commission (EC) Grants Marketing Authorization For Gilead’s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection
11/23/2015
-
Spring Bank Pharmaceuticals, Inc. Announces Clinical Trial Collaboration With Gilead For Hepatitis B (HBV) Phase 2 Clinical Trial
11/19/2015
-
Gilead’s Zydelig Combined With Bendamustine And Rituximab Shows Superior Efficacy To Bendamustine/Rituximab In Phase III Study Of Patients With Relapsed Chronic Lymphocytic Leukemia
11/16/2015
-
Gilead Release: Multiple Scientific Presentations At The Liver Meeting 2015 Further Highlight The Utility Of Sofosbuvir-Based Hepatitis C Therapies
11/16/2015
-
Gilead Presents New Data At The Liver Meeting 2015
11/16/2015
-
Gilead, Sanofi Scored Lowest in Disclosing Clinical Trial Data While GlaxoSmithKline, Johnson & Johnson and Pfizer Ranked Highest
11/13/2015
-
FDA Approves Gilead's Harvoni for Expanded Use
11/13/2015
-
X-Rx Announces Autotaxin Inhibitor Collaboration With Gilead
11/11/2015
-
Gilead's Blockbuster Sovaldi Linked to Slower Heartbeats and Puts Patients at Risk of Passing Out
11/6/2015
-
FDA Approves Gilead’s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide) For Treatment Of HIV-1 Infection
11/5/2015
-
ViiV Healthcare Hitting Hard But Gilead Management is Well-Prepared
11/4/2015
-
Gilead and WuXi PharmaTech Partner Up in China
11/2/2015
-
Gilead Submits New Drug Application To U.S. FDA For Fixed-Dose Combination Of Sofosbuvir/Velpatasvir For Treatment Of All Six Genotypes Of Hepatitis C
10/29/2015
-
Gilead Announces Third Quarter 2015 Financial Results
10/28/2015